357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

Subjects

Subjects :

First line treatment
Oncology
medicine.medical_specialty
business.industry
Internal medicine
medicine
Phase (waves)
Hematology
Pembrolizumab
Open label
business
Triple-negative breast cancer

Details

ISSN :

09237534

Volume :

31

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........3c0e037c6879d6afce29d096815a24d9

Full Text :

https://doi.org/10.1016/j.annonc.2020.08.459